{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T04:14:02Z","timestamp":1790828042128,"version":"4.1.0"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,19]],"date-time":"2024-08-19T00:00:00Z","timestamp":1724025600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,8,19]],"date-time":"2024-08-19T00:00:00Z","timestamp":1724025600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100021171","name":"Basic and Applied Basic Research Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2023A1515110236"],"award-info":[{"award-number":["2023A1515110236"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021171","name":"Basic and Applied Basic Research Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2022A1515110828"],"award-info":[{"award-number":["2022A1515110828"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82300252"],"award-info":[{"award-number":["82300252"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Guangdong Key Laboratory of Immune Regulation and Immunotherapy","award":["2022B1212010009"],"award-info":[{"award-number":["2022B1212010009"]}]},{"name":"Guangdong Natural Science Foundation Outstanding Youth Project","award":["2022B1515020050"],"award-info":[{"award-number":["2022B1515020050"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Exp Hematol Oncol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Epstein-Barr virus (EBV) related post-transplant lymphoproliferative disorder (EBV-PTLD) is a life-threatening complication after hematopoietic stem cell transplantation (HSCT) or solid organ transplantation (SOT), for which no standard therapeutic means have been developed. Significant increase expression of natural killer group 2 member D ligands (NKG2DLs) was observed on B-lymphoblastoid cells of EBV-PTLD, indicating NKG2DLs as potential therapeutic targets for treatment of EBV-PTLD. In this study, the recombinant constructs of NKG2D CAR and IL-15\/IL-15R\u03b1-NKG2D CAR were generated with a retroviral vector and then transduced to human T cells to produce NKG2D CAR-T and IL-15\/IL-15R\u03b1-NKG2D CAR-T cells, respectively. B-lymphoblastoid cell lines (B-LCLs) and the xenografted mouse models were established to evaluate the efficacy of these CAR-T cells. IL-15\/IL-15R\u03b1-NKG2D CAR-T cells exhibited superior proliferation and antigen-specific cytotoxic effect compared to NKG2D CAR-T, as IL-15\/IL-15R\u03b1 signaling promoted the expansion of less differentiated central memory T cells (T<jats:sub>CM<\/jats:sub>) and increased expression of CD107a and IFN-\u03b3. Moreover, EBV DNA load was dramatically reduced, and 80% B-LCL cells were eliminated by IL-15\/IL-15R\u03b1-NKG2D CAR-T cells after co-culturing. In-vivo study confirmed that IL-15\/IL-15R\u03b1-NKG2D CAR-T cell therapy significantly enhanced antiviral efficacy in mice, as the serum load of EBV after IL-15\/IL-15R\u03b1-NKG2D CAR-T cell infusion was 1500 times lower than the untreated control (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001). The enhanced efficacy of IL-15\/IL-15R\u03b1-NKG2D CAR T cells was probably due to the IL-15\/IL-15R\u03b1 signaling improved homing and persistence of NKG2D CAR-T cells in vivo, and increased the production of IFN-\u03b3, Perforin, and Granulysin. In conclusion, NKG2D CAR-T cells co-expressing IL-15\/IL-15R\u03b1 promoted the central memory CAR T cell proliferation and improved the homing and persistence of CAR T cells in vivo, resulting in enhanced anti-tumor and anti-viral effects in treating EBV-PTLD.<\/jats:p>","DOI":"10.1186\/s40164-024-00553-z","type":"journal-article","created":{"date-parts":[[2024,8,19]],"date-time":"2024-08-19T13:02:57Z","timestamp":1724072577000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Efficacy of NKG2D CAR-T cells with IL-15\/IL-15R\u03b1 signaling for treating Epstein-Barr virus-associated lymphoproliferative disorder"],"prefix":"10.1186","volume":"13","author":[{"given":"Qiusui","family":"Mai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bailin","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shikai","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanwen","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunyi","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinfeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinfeng","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liqin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongshui","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengyao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,19]]},"reference":[{"key":"553_CR1","doi-asserted-by":"crossref","first-page":"3652","DOI":"10.1016\/j.cell.2022.08.026","volume":"185","author":"B Damania","year":"2022","unstructured":"Damania B, Kenney SC, Raab-Traub N. Epstein-Barr virus: Biology and clinical disease. Cell. 2022;185:3652\u201370.","journal-title":"Cell"},{"key":"553_CR2","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1056\/NEJM200008173430707","volume":"343","author":"JI Cohen","year":"2000","unstructured":"Cohen JI. Epstein\u2013Barr Virus infection. N Engl J Med. 2000;343:481\u201392.","journal-title":"N Engl J Med"},{"key":"553_CR3","doi-asserted-by":"crossref","first-page":"183","DOI":"10.3390\/microorganisms7060183","volume":"7","author":"S Jangra","year":"2019","unstructured":"Jangra S, Yuen K-S, Botelho MG, Jin D-Y. Epstein-Barr Virus and Innate Immunity: friends or foes? Microorganisms. 2019;7:183.","journal-title":"Microorganisms"},{"key":"553_CR4","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jaci.2005.05.038","volume":"116","author":"DA Thorley-Lawson","year":"2005","unstructured":"Thorley-Lawson DA. EBV the prototypical human tumor virus\u2014just how bad is it? J Allergy Clin Immunol. 2005;116:251\u201361.","journal-title":"J Allergy Clin Immunol"},{"key":"553_CR5","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/bjh.18763","volume":"201","author":"SA Atallah-Yunes","year":"2023","unstructured":"Atallah-Yunes SA, Salman O, Robertson MJ. Post\u2010transplant lymphoproliferative disorder: update on treatment and novel therapies. Br J Haematol. 2023;201:383\u201395.","journal-title":"Br J Haematol"},{"key":"553_CR6","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.canlet.2015.08.007","volume":"369","author":"MR Petrara","year":"2015","unstructured":"Petrara MR, Giunco S, Serraino D, Dolcetti R, De Rossi A. Post-transplant lymphoproliferative disorders: from epidemiology to pathogenesis-driven treatment. Cancer Lett. 2015;369:37\u201344.","journal-title":"Cancer Lett"},{"key":"553_CR7","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1182\/blood.2023020075","volume":"142","author":"JE Amengual","year":"2023","unstructured":"Amengual JE, Pro B. How I treat posttransplant lymphoproliferative disorder. Blood. 2023;142:1426\u201337.","journal-title":"Blood"},{"key":"553_CR8","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/hon.3139","volume":"41","author":"TG Gross","year":"2023","unstructured":"Gross TG, Rubinstein JD. Post-transplant lymphoproliferative disease in children, adolescents, and young adults. Hematol Oncol. 2023;41:48\u201356.","journal-title":"Hematol Oncol"},{"key":"553_CR9","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1016\/j.bbmt.2019.08.006","volume":"25","author":"S Pagliuca","year":"2019","unstructured":"Pagliuca S, Bommier C, Michonneau D, Meignin V, Salmona M, Robin M, et al. Epstein-Barr Virus-Associated Post-transplantation Lymphoproliferative Disease in patients who received Anti-CD20 after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2019;25:2490\u2013500.","journal-title":"Biol Blood Marrow Transplant"},{"key":"553_CR10","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1111\/tri.14107","volume":"34","author":"J-Y Liu","year":"2021","unstructured":"Liu J-Y, Zhang J-M, Zhan H-S, Sun L-Y, Wei L. EBV-specific cytotoxic T lymphocytes for refractory EBV-associated post-transplant lymphoproliferative disorder in solid organ transplant recipients: a systematic review. Transpl Int. 2021;34:2483\u201393.","journal-title":"Transpl Int"},{"key":"553_CR11","doi-asserted-by":"crossref","first-page":"4792","DOI":"10.1182\/blood-2009-07-228387","volume":"114","author":"J Brewin","year":"2009","unstructured":"Brewin J, Mancao C, Straathof K, Karlsson H, Samarasinghe S, Amrolia PJ, et al. Generation of EBV-specific cytotoxic T cells that are resistant to calcineurin inhibitors for the treatment of posttransplantation lymphoproliferative disease. Blood. 2009;114:4792\u2013803.","journal-title":"Blood"},{"key":"553_CR12","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1182\/blood-2006-12-063008","volume":"110","author":"T Haque","year":"2007","unstructured":"Haque T, Wilkie GM, Jones MM, Higgins CD, Urquhart G, Wingate P, et al. Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. Blood. 2007;110:1123\u201331.","journal-title":"Blood"},{"key":"553_CR13","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1200\/JCO.2013.51.5304","volume":"32","author":"CM Bollard","year":"2014","unstructured":"Bollard CM, Gottschalk S, Torrano V, Diouf O, Ku S, Hazrat Y, et al. Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins. J Clin Oncol. 2014;32:798\u2013808.","journal-title":"J Clin Oncol"},{"key":"553_CR14","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s11899-019-00521-z","volume":"14","author":"W Jiang","year":"2019","unstructured":"Jiang W, Withers B, Sutrave G, Clancy LE, Yong MI, Blyth E. Pathogen-specific T cells beyond CMV, EBV and Adenovirus. Curr Hematol Malig Rep. 2019;14:247\u201360.","journal-title":"Curr Hematol Malig Rep"},{"key":"553_CR15","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.omto.2020.08.005","volume":"18","author":"C Slabik","year":"2020","unstructured":"Slabik C, Kalbarczyk M, Danisch S, Zeidler R, Klawonn F, Volk V, et al. CAR-T cells targeting Epstein-Barr Virus gp350 validated in a Humanized Mouse Model of EBV infection and lymphoproliferative disease. Mol Therapy - Oncolytics. 2020;18:504\u201324.","journal-title":"Mol Therapy - Oncolytics"},{"key":"553_CR16","doi-asserted-by":"crossref","first-page":"e000736","DOI":"10.1136\/jitc-2020-000736","volume":"8","author":"AC Dragon","year":"2020","unstructured":"Dragon AC, Zimmermann K, Nerreter T, Sandfort D, Lahrberg J, Kl\u00f6\u00df S, et al. CAR-T cells and TRUCKs that recognize an EBNA-3\u00a0C-derived epitope presented on HLA-B*35 control Epstein-Barr virus-associated lymphoproliferation. J Immunother Cancer. 2020;8:e000736.","journal-title":"J Immunother Cancer"},{"key":"553_CR17","doi-asserted-by":"crossref","first-page":"468","DOI":"10.7555\/JBR.28.20140066","volume":"28","author":"X Tang","year":"2014","unstructured":"Tang X, Zhou Y, Li W, Tang Q, Chen R, Zhu J, et al. T cells expressing a LMP1-specific chimeric antigen receptor mediate antitumor effects against LMP1-positive nasopharyngeal carcinoma cells in vitro and in vivo. J Biomed Res. 2014;28:468\u201375.","journal-title":"J Biomed Res"},{"key":"553_CR18","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1038\/s41409-020-01145-1","volume":"56","author":"E Luttwak","year":"2021","unstructured":"Luttwak E, Hagin D, Perry C, Wolach O, Itchaki G, Amit O, et al. Anti-CD19 CAR-T therapy for EBV-negative posttransplantation lymphoproliferative disease-a single center case series. Bone Marrow Transpl. 2021;56:1031\u20137.","journal-title":"Bone Marrow Transpl"},{"key":"553_CR19","doi-asserted-by":"crossref","first-page":"709370","DOI":"10.3389\/fonc.2021.709370","volume":"11","author":"N Yan","year":"2021","unstructured":"Yan N, Wang N, Zhang P, Wang G, Mao X, Peng D, et al. Case Report: successful chimeric Antigen receptor T cell therapy in haploidentical-allogeneic stem cell transplant patients with post-transplant lymphoproliferative disorder. Front Oncol. 2021;11:709370.","journal-title":"Front Oncol"},{"key":"553_CR20","doi-asserted-by":"crossref","first-page":"7542","DOI":"10.3390\/jcm11247542","volume":"11","author":"M Clerico","year":"2022","unstructured":"Clerico M, Dogliotti I, Aroldi A, Consoli C, Giaccone L, Bruno B, et al. Post-transplant lymphoproliferative disease (PTLD) after allogeneic hematopoietic stem cell transplantation: Biology and Treatment options. J Clin Med. 2022;11:7542.","journal-title":"J Clin Med"},{"key":"553_CR21","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1097\/PPO.0000000000000029","volume":"20","author":"CL Sentman","year":"2014","unstructured":"Sentman CL, Meehan KR. NKG2D CARs as cell therapy for Cancer. Cancer J. 2014;20:156\u20139.","journal-title":"Cancer J"},{"key":"553_CR22","doi-asserted-by":"crossref","first-page":"ltab018","DOI":"10.1093\/immadv\/ltab018","volume":"1","author":"S Curio","year":"2021","unstructured":"Curio S, Jonsson G, Marinovi\u0107 S. A summary of current NKG2D-based CAR clinical trials. Immunother Adv. 2021;1:ltab018.","journal-title":"Immunother Adv"},{"key":"553_CR23","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.coi.2018.02.004","volume":"51","author":"P Dhar","year":"2018","unstructured":"Dhar P, Wu JD. NKG2D and its ligands in cancer. Curr Opin Immunol. 2018;51:55\u201361.","journal-title":"Curr Opin Immunol"},{"key":"553_CR24","doi-asserted-by":"crossref","first-page":"713158","DOI":"10.3389\/fimmu.2021.713158","volume":"12","author":"MB Fuertes","year":"2021","unstructured":"Fuertes MB, Domaica CI, Zwirner NW. Leveraging NKG2D ligands in Immuno-Oncology. Front Immunol. 2021;12:713158.","journal-title":"Front Immunol"},{"key":"553_CR25","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1089\/hum.2012.143","volume":"24","author":"D-G Song","year":"2013","unstructured":"Song D-G, Ye Q, Santoro S, Fang C, Best A, Powell DJ. Chimeric NKG2D CAR-expressing T cell-mediated attack of human ovarian cancer is enhanced by histone deacetylase inhibition. Hum Gene Ther. 2013;24:295\u2013305.","journal-title":"Hum Gene Ther"},{"key":"553_CR26","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s13045-018-0635-z","volume":"11","author":"Y Han","year":"2018","unstructured":"Han Y, Xie W, Song D-G, Powell DJ. Control of triple-negative breast cancer using ex vivo self-enriched, costimulated NKG2D CAR T cells. J Hematol Oncol. 2018;11:92.","journal-title":"J Hematol Oncol"},{"key":"553_CR27","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/s41408-021-00537-w","volume":"11","author":"A Leivas","year":"2021","unstructured":"Leivas A, Valeri A, C\u00f3rdoba L, Garc\u00eda-Ortiz A, Ortiz A, S\u00e1nchez-Vega L, et al. NKG2D-CAR-transduced natural killer cells efficiently target multiple myeloma. Blood Cancer J. 2021;11:146.","journal-title":"Blood Cancer J"},{"key":"553_CR28","doi-asserted-by":"crossref","first-page":"5824","DOI":"10.1158\/1078-0432.CCR-17-0075","volume":"23","author":"L Fern\u00e1ndez","year":"2017","unstructured":"Fern\u00e1ndez L, Metais J-Y, Escudero A, Vela M, Valent\u00edn J, Vallcorba I, et al. Memory T cells expressing an NKG2D-CAR efficiently Target Osteosarcoma cells. Clin Cancer Res. 2017;23:5824\u201335.","journal-title":"Clin Cancer Res"},{"key":"553_CR29","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1126\/science.1240094","volume":"341","author":"B Chaigne-Delalande","year":"2013","unstructured":"Chaigne-Delalande B, Li F-Y, O\u2019Connor GM, Lukacs MJ, Jiang P, Zheng L, et al. Mg 2+ regulates cytotoxic functions of NK and CD8 T cells in chronic EBV infection through NKG2D. Science. 2013;341:186\u201391.","journal-title":"Science"},{"key":"553_CR30","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","volume":"11","author":"RC Sterner","year":"2021","unstructured":"Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021;11:69.","journal-title":"Blood Cancer J"},{"key":"553_CR31","doi-asserted-by":"crossref","first-page":"1101495","DOI":"10.3389\/fimmu.2023.1101495","volume":"14","author":"X Zhang","year":"2023","unstructured":"Zhang X, Zhang H, Lan H, Wu J, Xiao Y. CAR-T cell therapy in multiple myeloma: current limitations and potential strategies. Front Immunol. 2023;14:1101495.","journal-title":"Front Immunol"},{"key":"553_CR32","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1074\/jbc.M508624200","volume":"281","author":"E Mortier","year":"2006","unstructured":"Mortier E, Qu\u00e9m\u00e9ner A, Vusio P, Lorenzen I, Boublik Y, Gr\u00f6tzinger J, et al. Soluble interleukin-15 receptor alpha (IL-15R alpha)-sushi as a selective and potent agonist of IL-15 action through IL-15R beta\/gamma. Hyperagonist IL-15 x IL-15R alpha fusion proteins. J Biol Chem. 2006;281:1612\u20139.","journal-title":"J Biol Chem"},{"key":"553_CR33","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/0022-2836(91)90666-T","volume":"219","author":"DG Norman","year":"1991","unstructured":"Norman DG, Barlow PN, Baron M, Day AJ, Sim RB, Campbell ID. Three-dimensional structure of a complement control protein module in solution. J Mol Biol. 1991;219:717\u201325.","journal-title":"J Mol Biol"},{"key":"553_CR34","doi-asserted-by":"crossref","first-page":"26978","DOI":"10.1074\/jbc.274.38.26978","volume":"274","author":"S Dubois","year":"1999","unstructured":"Dubois S, Magrangeas F, Lehours P, Raher S, Bernard J, Boisteau O, et al. Natural splicing of exon 2 of human interleukin-15 receptor alpha-chain mRNA results in a shortened form with a distinct pattern of expression. J Biol Chem. 1999;274:26978\u201384.","journal-title":"J Biol Chem"},{"key":"553_CR35","first-page":"4411","volume":"112","author":"Z Wu","year":"2008","unstructured":"Wu Z, Xue H-H, Bernard J, Zeng R, Issakov D, Bollenbacher-Reilley J, et al. The IL-15 receptor {alpha} chain cytoplasmic domain is critical for normal IL-15Ralpha function but is not required for trans-presentation. Blood. 2008;112:4411\u20139.","journal-title":"Blood"},{"key":"553_CR36","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1182\/blood-2020-141606","volume":"136","author":"V Bachanova","year":"2020","unstructured":"Bachanova V, Cayci Z, Lewis D, Maakaron JE, Janakiram M, Bartz A, et al. Initial clinical activity of FT596, a first-in-Class, Multi-antigen targeted, off-the-Shelf, iPSC-Derived CD19 CAR NK Cell Therapy in Relapsed\/Refractory B-Cell Lymphoma. Blood. 2020;136:8.","journal-title":"Blood"},{"key":"553_CR37","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1186\/s12967-024-04982-6","volume":"22","author":"J Ye","year":"2024","unstructured":"Ye J, Liu Q, He Y, Song Z, Lin B, Hu Z, et al. Combined therapy of CAR-IL-15\/IL-15R\u03b1-T cells and GLIPR1 knockdown in cancer cells enhanced anti-tumor effect against gastric cancer. J Transl Med. 2024;22:171.","journal-title":"J Transl Med"},{"key":"553_CR38","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1186\/s12967-022-03626-x","volume":"20","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Zhuang Q, Wang F, Zhang C, Xu C, Gu A, et al. Co-expression IL-15 receptor alpha with IL-15 reduces toxicity via limiting IL-15 systemic exposure during CAR-T immunotherapy. J Transl Med. 2022;20:432.","journal-title":"J Transl Med"},{"key":"553_CR39","doi-asserted-by":"crossref","first-page":"3635","DOI":"10.1158\/0008-5472.CAN-21-0035","volume":"81","author":"R Ma","year":"2021","unstructured":"Ma R, Lu T, Li Z, Teng K-Y, Mansour AG, Yu M, et al. An oncolytic virus expressing IL15\/IL15R\u03b1 combined with off-the-Shelf EGFR-CAR NK cells targets Glioblastoma. Cancer Res. 2021;81:3635\u201348.","journal-title":"Cancer Res"},{"key":"553_CR40","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/nri1901","volume":"6","author":"TA Waldmann","year":"2006","unstructured":"Waldmann TA. The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nat Rev Immunol. 2006;6:595\u2013601.","journal-title":"Nat Rev Immunol"},{"key":"553_CR41","unstructured":"Kanegane H. Activation of naive and memory T cells by interleukin-15."},{"key":"553_CR42","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1182\/blood.V88.1.230.230","volume":"88","author":"H Kanegane","year":"1996","unstructured":"Kanegane H, Tosato G. Activation of naive and memory T cells by interleukin-15. Blood. 1996;88:230\u20135.","journal-title":"Blood"},{"key":"553_CR43","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1007\/BF00279094","volume":"73","author":"H Neitzel","year":"1986","unstructured":"Neitzel H. A routine method for the establishment of permanent growing lymphoblastoid cell lines. Hum Genet. 1986;73:320\u20136.","journal-title":"Hum Genet"},{"key":"553_CR44","first-page":"240","volume":"29","author":"X Yi","year":"2021","unstructured":"Yi X, Wen C, Gu S, Guo L, Tang L, Wang W. [Hepatitis B virus antigen peptide presentation by Epstein-Barr virus-transformed peripheral blood B cells]. Chin J Hepatol. 2021;29:240\u20135.","journal-title":"Chin J Hepatol"},{"key":"553_CR45","doi-asserted-by":"crossref","first-page":"1130442","DOI":"10.3389\/fimmu.2023.1130442","volume":"14","author":"B He","year":"2023","unstructured":"He B, Mai Q, Pang Y, Deng S, He Y, Xue R, et al. Cytokines induced memory-like NK cells engineered to express CD19 CAR exhibit enhanced responses against B cell malignancies. Front Immunol. 2023;14:1130442.","journal-title":"Front Immunol"},{"key":"553_CR46","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1002\/ijc.32201","volume":"145","author":"S Stock","year":"2019","unstructured":"Stock S, \u00dcbelhart R, Schubert M-L, Fan F, He B, Hoffmann J-M, et al. Idelalisib for optimized CD19-specific chimeric antigen receptor T cells in chronic lymphocytic leukemia patients. Int J Cancer. 2019;145:1312\u201324.","journal-title":"Int J Cancer"},{"key":"553_CR47","doi-asserted-by":"crossref","first-page":"951","DOI":"10.3109\/14653241003628167","volume":"12","author":"BA Williams","year":"2010","unstructured":"Williams BA, Wang X-H, Keating A. Clonogenic assays measure leukemia stem cell killing not detectable by chromium release and flow cytometric cytotoxicity assays. Cytotherapy. 2010;12:951\u201360.","journal-title":"Cytotherapy"},{"key":"553_CR48","first-page":"1938704","volume":"2020","author":"I Macchia","year":"2020","unstructured":"Macchia I, La Sorsa V, Ruspantini I, Sanchez M, Tirelli V, Carollo M, et al. Multicentre Harmonisation of a six-Colour Flow Cytometry Panel for Na\u00efve\/Memory T Cell Immunomonitoring. J Immunol Res. 2020;2020:1938704.","journal-title":"J Immunol Res"},{"key":"553_CR49","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.omtm.2021.10.014","volume":"23","author":"Z Du","year":"2021","unstructured":"Du Z, Ng YY, Zha S, Wang S. piggyBac system to co-express NKG2D CAR and IL-15 to augment the in vivo persistence and anti-AML activity of human peripheral blood NK cells. Mol Therapy - Methods Clin Dev. 2021;23:582\u201396.","journal-title":"Mol Therapy - Methods Clin Dev"},{"key":"553_CR50","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/j.ymthe.2019.03.011","volume":"27","author":"L Xiao","year":"2019","unstructured":"Xiao L, Cen D, Gan H, Sun Y, Huang N, Xiong H, et al. Adoptive transfer of NKG2D CAR mRNA-Engineered Natural Killer cells in Colorectal Cancer patients. Mol Ther. 2019;27:1114\u201325.","journal-title":"Mol Ther"},{"key":"553_CR51","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S1359-6101(02)00029-1","volume":"13","author":"JP Lodolce","year":"2002","unstructured":"Lodolce JP, Burkett PR, Koka RM, Boone DL, Ma A. Regulation of lymphoid homeostasis by interleukin-15. Cytokine Growth Factor Rev. 2002;13:429\u201339.","journal-title":"Cytokine Growth Factor Rev"},{"key":"553_CR52","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1073\/pnas.0610115104","volume":"104","author":"N Sato","year":"2007","unstructured":"Sato N, Patel HJ, Waldmann TA, Tagaya Y. The IL-15\/IL-15Ralpha on cell surfaces enables sustained IL-15 activity and contributes to the long survival of CD8 memory T cells. Proc Natl Acad Sci U S A. 2007;104:588\u201393.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"553_CR53","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","volume":"24","author":"JA Fraietta","year":"2018","unstructured":"Fraietta JA, Lacey SF, Orlando EJ, Pruteanu-Malinici I, Gohil M, Lundh S, et al. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat Med. 2018;24:563\u201371.","journal-title":"Nat Med"},{"key":"553_CR54","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/25785826.2019.1698261","volume":"43","author":"M Ando","year":"2020","unstructured":"Ando M, Ito M, Srirat T, Kondo T, Yoshimura A. Memory T cell, exhaustion, and tumor immunity. Immunological Med. 2020;43:1\u20139.","journal-title":"Immunological Med"},{"key":"553_CR55","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1158\/2326-6066.CIR-18-0466","volume":"7","author":"D Alizadeh","year":"2019","unstructured":"Alizadeh D, Wong RA, Yang X, Wang D, Pecoraro JR, Kuo C-F, et al. IL15 enhances CAR-T cell antitumor activity by reducing mTORC1 activity and preserving their stem cell memory phenotype. Cancer Immunol Res. 2019;7:759\u201372.","journal-title":"Cancer Immunol Res"},{"key":"553_CR56","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1038\/nm.2446","volume":"17","author":"L Gattinoni","year":"2011","unstructured":"Gattinoni L, Lugli E, Ji Y, Pos Z, Paulos CM, Quigley MF, et al. A human memory T cell subset with stem cell-like properties. Nat Med. 2011;17:1290\u20137.","journal-title":"Nat Med"},{"key":"553_CR57","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1146\/annurev.immunol.22.012703.104702","volume":"22","author":"F Sallusto","year":"2004","unstructured":"Sallusto F, Geginat J, Lanzavecchia A. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol. 2004;22:745\u201363.","journal-title":"Annu Rev Immunol"},{"key":"553_CR58","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1089\/hum.2012.247","volume":"24","author":"AA Hombach","year":"2013","unstructured":"Hombach AA, Chmielewski M, Rappl G, Abken H. Adoptive immunotherapy with redirected T cells produces CCR7- cells that are trapped in the periphery and benefit from combined CD28-OX40 costimulation. Hum Gene Ther. 2013;24:259\u201369.","journal-title":"Hum Gene Ther"},{"key":"553_CR59","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1172\/JCI46110","volume":"121","author":"B Savoldo","year":"2011","unstructured":"Savoldo B, Ramos CA, Liu E, Mims MP, Keating MJ, Carrum G, et al. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest. 2011;121:1822\u20136.","journal-title":"J Clin Invest"},{"key":"553_CR60","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1007\/s00262-011-0977-7","volume":"60","author":"S Yang","year":"2011","unstructured":"Yang S, Gattinoni L, Liu F, Ji Y, Yu Z, Restifo NP, et al. In vitro generated anti-tumor T lymphocytes exhibit distinct subsets mimicking in vivo antigen-experienced cells. Cancer Immunol Immunother. 2011;60:739\u201349.","journal-title":"Cancer Immunol Immunother"},{"key":"553_CR61","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s00262-016-1949-8","volume":"66","author":"C Chen","year":"2017","unstructured":"Chen C, Li K, Jiang H, Song F, Gao H, Pan X, et al. Development of T cells carrying two complementary chimeric antigen receptors against glypican-3 and asialoglycoprotein receptor 1 for the treatment of hepatocellular carcinoma. Cancer Immunol Immunother. 2017;66:475\u201389.","journal-title":"Cancer Immunol Immunother"},{"key":"553_CR62","first-page":"2587","volume":"141","author":"M Biondi","year":"2023","unstructured":"Biondi M, Tettamanti S, Galimberti S, Cerina B, Tomasoni C, Piazza R, et al. Selective homing of CAR-CIK cells to the bone marrow niche enhances control of the acute myeloid leukemia burden. Blood. 2023;141:2587\u201398.","journal-title":"Blood"},{"key":"553_CR63","doi-asserted-by":"crossref","unstructured":"Ran G, he, Lin Yqing, Tian L, Zhang T, Yan D, mei, Yu J et al. hua,. Natural killer cell homing and trafficking in tissues and tumors: from biology to application. Sig Transduct Target Ther. 2022;7:205.","DOI":"10.1038\/s41392-022-01058-z"},{"key":"553_CR64","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s10875-006-6532-1","volume":"26","author":"LA Jurgens","year":"2006","unstructured":"Jurgens LA, Khanna R, Weber J, Orentas RJ. Transduction of primary lymphocytes with Epstein-Barr virus (EBV) latent membrane protein-specific T-cell receptor induces lysis of virus-infected cells: a novel strategy for the treatment of Hodgkin\u2019s disease and nasopharyngeal carcinoma. J Clin Immunol. 2006;26:22\u201332.","journal-title":"J Clin Immunol"},{"key":"553_CR65","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1002\/eji.1830270227","volume":"27","author":"A Durandy","year":"1997","unstructured":"Durandy A, Le Deist F, Emile JF, Debatin K, Fischer A. Sensitivity of Epstein-Barr virus-induced B cell tumor to apoptosis mediated by anti-CD95\/Apo-1\/fas antibody. Eur J Immunol. 1997;27:538\u201343.","journal-title":"Eur J Immunol"},{"key":"553_CR66","doi-asserted-by":"crossref","first-page":"580328","DOI":"10.3389\/fimmu.2020.580328","volume":"11","author":"L Driouk","year":"2020","unstructured":"Driouk L, Gicobi JK, Kamihara Y, Rutherford K, Dranoff G, Ritz J, et al. Chimeric Antigen Receptor T Cells targeting NKG2D-Ligands Show Robust Efficacy against Acute myeloid leukemia and T-Cell Acute Lymphoblastic Leukemia. Front Immunol. 2020;11:580328.","journal-title":"Front Immunol"},{"key":"553_CR67","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.annonc.2020.10.478","volume":"32","author":"M-L Schubert","year":"2021","unstructured":"Schubert M-L, Schmitt M, Wang L, Ramos CA, Jordan K, M\u00fcller-Tidow C, et al. Side-effect management of chimeric antigen receptor (CAR) T-cell therapy. Ann Oncol. 2021;32:34\u201348.","journal-title":"Ann Oncol"}],"updated-by":[{"DOI":"10.1186\/s40164-024-00559-7","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T00:00:00Z","timestamp":1726099200000}}],"container-title":["Experimental Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40164-024-00553-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40164-024-00553-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40164-024-00553-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T14:07:19Z","timestamp":1726150039000},"score":1,"resource":{"primary":{"URL":"https:\/\/ehoonline.biomedcentral.com\/articles\/10.1186\/s40164-024-00553-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,19]]},"references-count":67,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["553"],"URL":"https:\/\/doi.org\/10.1186\/s40164-024-00553-z","relation":{"correction":[{"id-type":"doi","id":"10.1186\/s40164-024-00559-7","asserted-by":"object"}]},"ISSN":["2162-3619"],"issn-type":[{"value":"2162-3619","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,19]]},"assertion":[{"value":"17 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2024","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s40164-024-00559-7","URL":"https:\/\/doi.org\/10.1186\/s40164-024-00559-7","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research was approved by the Ethics Committee of Southern Medical University (No. SMUL2023080) and Guangzhou Blood Center (No. GZBC2022068). All procedures with mice were performed in accordance with the relevant requirements by institutional animal care and used Committee of Southern Medical University. The authors have received permission to publish the research data from all the participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"85"}}